WASHINGTON, D.C. — Federal health officials are investing up to $139.4 million in new research to accelerate the development of mental health treatments, including emerging therapies such as digital tools, brain stimulation, and psychedelics.
What This Means for You
- New mental health treatments could reach patients faster
- Research aims to match therapies to individuals more effectively
- Federal funding may expand access to innovative care options
The funding, announced by the Advanced Research Projects Agency for Health, supports a new initiative called Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health, or EVIDENT.
The program is designed to improve how treatments are tested and approved by developing objective ways to measure whether therapies are working — rather than relying primarily on patient-reported symptoms or trial-and-error approaches.
Why the Initiative Matters
Federal officials say current mental health care often depends on subjective assessments, such as patient surveys, and can involve multiple failed treatment attempts before finding an effective option.
EVIDENT aims to change that by creating measurable indicators — known as clinical endpoints — that can show how a patient is responding to treatment based on biological data.
Over a lifetime, about half of Americans experience mental or behavioral health conditions, with higher rates among veterans. At the same time, spending on behavioral health and substance use treatment has increased from about $40.9 billion annually in 2000 to more than $140 billion today.
Focus on New and Emerging Therapies
The initiative will support research into rapid-acting treatments, including neuromodulation — therapies that use targeted stimulation of the nervous system — and neuroplastogens, which are substances that may help the brain form new connections.
It will also include research into the use of psychedelics under controlled conditions for serious mental illness. At least $50 million of the funding is set aside to match state investments in psychedelic research.
HHS Secretary Robert F. Kennedy Jr. said the effort is intended to improve understanding of how treatments work.
“Through this data, we’ll be able to match the right treatment to the right person and know how an individual will respond before it begins,” Kennedy said.
Research Teams Selected
The first group of research teams includes universities, health technology companies, and clinical research organizations across the United States and Canada.
Their work will focus on collecting and analyzing large amounts of biological and clinical data over time — including genetic information, hormone levels, and real-world patient outcomes — to better understand how treatments affect the body.
Some teams will study psilocybin, a psychedelic compound, in clinical trials for conditions such as anxiety, while others will explore approaches like wearable health monitoring, gut microbiome interventions, and brain stimulation technologies.
Building a Data-Driven System
The initiative is structured around four key research questions: how to measure treatment effects objectively, what happens in the body during treatment, which patients are most likely to respond, and how to build a shared data system.
Officials said the goal is to move mental health care toward more precise, personalized treatment — similar to advances seen in other areas of medicine.
ARPA-H Director Alicia Jackson said the approach could reduce delays in finding effective care.
“Through EVIDENT, we are investing in objective, predictive measures that will help clinicians know much sooner whether a therapy is working for an individual patient,” Jackson said.
Next Steps
The agency said additional research teams will be selected on a rolling basis as the initiative expands.
Officials said the long-term goal is to generate data that can support faster regulatory approval of new treatments and reduce development costs, potentially improving access for patients nationwide.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.